CorePlus Puerto Rico Publishes Groundbreaking Study on Implementing 100% Quality Control in Cervical Cytology Using Whole Slide Imaging and Artificial Intelligence
CAROLINA, Puerto Rico, May 27, 2025 /PRNewswire/ — CorePlus, a leading precision pathology organization in Puerto Rico, has announced the publication of a landmark study validating the use of artificial intelligence (AI) and whole slide imaging (WSI) as a 100% quality control (QC) tool in cervical cytology workflows. The study was published in the prestigious peer-reviewed journal Cancer Cytopathology, underscoring its scientific rigor and clinical relevance.
Revolutionizing Cytology with AI and Digital Pathology
As digital pathology continues to advance into the field of cytopathology, laboratories are exploring alternatives to traditional manual microscopy screening. CorePlus evaluated the performance of the Techcyte SureView™ system—specifically designed for digital cytopathology—on 1,442 digitized slides from ThinPrep® and SurePath™ cervical cytology samples.
The slides were scanned using the 3DHISTECH P1000 DX scanner under both dry and water immersion scanning profiles. A board-certified cytopathologist reviewed AI-identified objects of interest and compared them to results obtained through traditional light microscopy.
Outstanding Results and Operational Efficiency
The study demonstrated that the SureView™ system using the water immersion profile significantly outperformed both dry scanning and manual microscopy in detecting squamous and glandular abnormalities. Key performance metrics included:
97% accuracy
82% sensitivity
99% specificity
98% negative predictive value
86% positive predictive value
In addition to its high diagnostic performance, the AI-assisted system considerably reduced review times and improved overall workflow efficiency.
A New Standard for Quality Control in Cervical Cytology
Following successful validation, CorePlus has fully integrated the Techcyte SureView™ system as a 100% QC tool in its laboratory operations. This marks a major step forward in adopting digital and AI technologies to enhance diagnostic accuracy, laboratory efficiency, and patient care.
'We have been able to achieve an unprecedented level of consistency and confidence in cervical cytology screening, every PAP Counts!' Mariano de Socarraz, Founder and Chief Executive Officer at CorePlus. 'Our team is proud to contribute to the advancement of digital pathology and demonstrate its real-world clinical impact.'
For access to the complete published study please visit: Implementing 100% quality control in a cervical cytology workflow using whole slide images and artificial intelligence provided by the Techcyte SureView™ System – Rivera Rolon – 2025 – Cancer Cytopathology – Wiley Online Library
About CorePlus
CorePlus is a state-of-the-art precision pathology organization based in Puerto Rico, committed to diagnostic excellence through innovation and technology. With a patient-centered approach and quality-driven processes, CorePlus is at the forefront of adopting artificial intelligence algorithms as decision support tools for our pathologists offering unprecedented accuracy and efficiency.
About Cancer Cytopathology
Cancer Cytopathology is a peer-reviewed medical journal published by the American Cancer Society. Internationally recognized, it focuses on the science and practice of cancer cytopathology. The journal publishes innovative research, clinical studies, and expert reviews aimed at improving diagnostic accuracy and outcomes in cancer management. The publication of the CorePlus study in Cancer Cytopathology highlights its significant contribution to the advancement of digital cytopathology in cancer diagnostics and quality control.
About Techcyte
Founded in 2013, Techcyte is transforming the practice of pathology with a unified pathology platform that digitizes lab workflows and offers AI tools that improve the efficiency and accuracy of diagnostic testing.
Our mission is to positively impact the health of humans, animals, and the environment through the use of artificial intelligence.
We do that by partnering with best-in-class labs, whole slide scanner manufacturers, AI vendors, diagnostic companies, hardware manufacturers, and solution providers. Together, we aim to deliver a unified clinical and anatomic pathology platform to labs and clinics around the world.
Visit www.techcyte.com for more information.
About Epredia
Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523) offers a unique array of end-to-end instruments for pathology workflows including tissue processors, microtomes, embedding stations, and a range of 3DHistech developed whole slide scanners from the single slide Pannoramic Desk II to the Pannoramic 1000 scanner. These scanners offer a single slide to 1000 slide capacity and a throughput of up to 85 slides per hour, including overnight scanning.
Visit www.epredia.com for more information.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
16 hours ago
- Malaysian Reserve
Illuminating ctDNA-MRD: Gene Solutions' K-CONNECT APAC 2025 Sparks Regional Collaboration in Precision Oncology
DA NANG, Vietnam, May 31, 2025 /PRNewswire/ — May 9-11, 2025, Gene Solutions, a pioneer in AI-driven precision oncology hosted K-CONNECT APAC 2025, a pivotal summit uniting over 100 distinguished oncologists and molecular biologists from nine Asia-Pacific countries. — This landmark event marked a significant milestone in advancing precision oncology, fostering collaboration, and driving innovation in the fields of circulating tumor DNA (ctDNA), Molecular Residual Disease (MRD), and Comprehensive Genomic Profiling (CGP). Under the theme 'Empowering the Potential of ctDNA-MRD,' 16 distinguished speakers and panelists shared clinical insights, breakthrough research, and innovative strategies for integrating ctDNA-MRD into cancer practice. 'While ctDNA and MRD are invisible to the eye, K-CONNECT APAC 2025 shed transformative light on their potential through regional collaboration and clinical innovation,' said Ida Deleskog Lindstrom, Global Medical Affairs Director at Gene Solutions. 'Illuminating ctDNA-MRD means revealing actionable insights that spark hope, clarity, and progress through molecular insights to transform precision oncology.' 'K-CONNECT APAC 2025 was a transformative moment for precision oncology in the Asia-Pacific, bringing together diverse expertise to translate ctDNA-MRD advancements into real-world clinical impact' said Professor Nick Pavlakis, Co-Chair of the summit and a leading medical oncologist from Australia. 'This summit has set a new benchmark for collaborative innovation, paving the way for personalized cancer care across the region' A First-of-Its-Kind Gathering in Asia-Pacific Gene Solutions, a regional pioneer in ctDNA-MRD testing, has supported over 6,000 cancer patients via its next generation comprehensive AI-powered K-TRACK® and K-4CARE® platforms. K-CONNECT APAC 2025 showcased its role in fostering cross-border expertise to accelerate adoption of precision diagnostics. The summit featured three key sessions shared by 16 esteemed experts K-CONNECT ACADEMIC Session: The Importance of ctDNA-MRD and CGP in Precision Oncology Unique Combination of Genomic & Transcriptomic Profiling with ctDNA-MRD Monitoring Key findings from Asia's First Real-World Study of ctDNA-MRD Monitoring in Solid Tumors. K-CONNECT CASE SHARING Session ctDNA-MRD Applications & Real-World Case Sharing in Colorectal, Lung and Breast cancers. K-CONNECT NEXT LANDMARK Session Genetic Testing Guided Personalized Immunotherapy in Refractory Solid Tumors. Triad of Impact– A Multi-omic Solution to Advance Precision Oncology Innovation. Beyond an Event — Establishing a Platform for Ongoing Impact K-CONNECT is evolving into a regional hub for knowledge exchange, clinical collaborations, and precision oncology innovation acceleration. Upcoming initiatives include: K-CONNECT Webinar Series – Ongoing expert-led case discussions Clinical Trials Collaboration – Cross-border partnerships with biopharma and research institutions Experience ctDNA-MRD Program – Hands-on implementation support for clinicians Knowledge Hub – A digital platform for APAC oncology insights Shaping the Future of Cancer Care K-CONNECT APAC 2025 solidified Gene Solutions' leadership in genetic testing and its commitment to advancing equitable access to innovative solutions to improve patient outcomes. By fostering collaboration and showcasing real-world impact, the summit laid the foundation for a more connected, data-driven, and patient-centered future in cancer care across the Asia-Pacific. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific. Explore more information at: MEDIA CONTACT: pr@
Malaysian Reserve
18 hours ago
- Malaysian Reserve
Biomarkers Market worth US$104.15 billion in 2030 with 10.8% CAGR
DELRAY BEACH, Fla., May 30, 2025 /PRNewswire/ — The global Biomarkers Market, valued at US$58.07 billion in 2024 stood at US$62.39 billion in 2025 and is projected to advance at a resilient CAGR of 10.8% from 2025 to 2030, culminating in a forecasted valuation of US$104.15 billion by the end of the period. This growth is supported by the growing use of biomarkers in drug development and the increasing role of companion diagnostics in advancing precision medicine. The rising number of cancer cases worldwide and increased funding for various types of research are other important factors propelling the market's growth. Moreover, advances in omics technologies, including genomics and proteomics, are now enabling the development of more sophisticated tests based on biomarkers. Many companies are now targeting new markets such as the Asia Pacific region, where there is a high demand for targeted diagnostics, thus creating new opportunities for biomarker-driven solutions. Download PDF Brochure: Browse in-depth TOC on 'Biomarkers Market' 700 – Tables54 – Figures510 – Pages By offering, the biomarkers market is categorized into consumables, services, and software. Consumables are further sub segmented into assay kits, reagents & chemicals, and columns & filters. The consumables segment accounted for the largest share of the global biomarkers market in 2024. The large share of consumables is due to the high and recurring demand for assay kits, reagents, and other consumables in biomarker-based research, diagnostics, and validation workflows, which ensures continuous usage across laboratories and clinical settings. Additionally, the growing number of biomarker-based studies and clinical trials has driven the need for reliable, high-throughput consumables that support reproducibility and scalability. Moreover, the increasing adoption of multiplex assay platforms, which require specialized consumables to detect multiple biomarkers from limited sample volumes, also supports the large share of the consumables segment. By type, the biomarkers market is categorized into safety, efficacy, and validation biomarkers. The efficacy biomarkers are sub segmented into predictive, surrogate, pharmacodynamics, and prognostic biomarkers. The safety biomarkers segment held the largest share in the biomarkers market in 2024. This can be attributed to the use of safety biomarkers in drug development to assess toxicity and identify potential adverse effects early in the development process. Regulatory agencies increasingly require safety biomarkers to ensure drug candidates meet safety standards before advancing to later stages of clinical trials. Additionally, pharmaceutical companies are investing in safety biomarker strategies to reduce the risk of late-stage failures and improve decision-making during preclinical and early clinical phases. By PCR technology, the biomarkers market is segmented by technology into immunoassays, NGS, PCR, mass spectrometry, chromatography, and other technologies. PCR technology, which is used for detecting, quantifying, and validating nucleic acid-based biomarkers, is estimated to register the highest CAGR during the forecast period of 2025-2030. This growth is supported by this technology's high sensitivity, cost-effectiveness, and broad applicability in detecting and quantifying genetic material. Companies can utilize this growth by expanding PCR-based test offerings, developing multiplex PCR kits, and integrating PCR platforms into biomarker-based diagnostics and companion tests. While PCR is expected to lead in growth, companies can also benefit from incorporating other technologies, such as NGS and MS, to support comprehensive biomarker analysis, particularly where high-throughput sequencing or protein-level insights are required. By geography, the biomarkers market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. In 2024, North America held the largest share in the biomarkers market due to its well-established healthcare infrastructure, high research and development spending, and strong presence of leading pharmaceutical and biotechnology companies. The region has a high adoption rate of advanced technologies, including next-generation sequencing and companion diagnostics, which support biomarker discovery and application across clinical and research settings. Additionally, favorable regulatory frameworks, availability of funding from government and private sources, and a growing focus on precision medicine have further driven the use of biomarkers. The increasing burden of chronic diseases such as cancer and cardiovascular conditions has also contributed to sustained demand for biomarker-based diagnostics and therapies in the region. Request Sample Pages : Key players in the biomarkers market include F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMÉRIEUX (France), Agilent Technologies, Inc. (US), and JSR Corporation (Japan). The market includes many other prominent companies and competitive startups/SMEs. F. Hoffmann-La Roche Ltd (Switzerland): F. Hoffmann-La Roche Ltd is a major player in the global biomarker market, leveraging its integrated diagnostics-pharmaceutical business model, strong geographical presence, and ongoing innovation. The company operates in two segments: Diagnostics and Pharmaceuticals, with the Diagnostics division encompassing Core Lab, Molecular Lab, Pathology Lab, Point of Care, and Diabetes Care. These divisions provide biomarker-based assays, digital platforms, and companion diagnostics for applications in oncology, cardiology, neurology, infectious diseases, and diabetes. In 2023, Roche's Diagnostics division processed over 29 billion tests across more than 100,000 platforms, reflecting strong global demand. The company launched over 20 diagnostic assays between 2022 and May 2025, including the FDA-approved VENTANA MET (SP44) RxDx Assay for non-squamous non-small cell lung cancer. Roche also actively pursues partnerships, such as collaborations with PathAI for AI-based pathology algorithms and with Neuron23 to utilize digital biomarkers in Parkinson's disease trials. Roche's integration of diagnostic development, test delivery, and data platforms, along with its global reach and AI-enabled R&D, enhances its leadership in the biomarker market. Merck KGaA (Germany) Merck KGaA is a major player in the biomarker market through its Life Science segment, which provides biomarker assays, consumables, software, and services for research and diagnostics. The Science & Lab Solutions division focuses on biomarker discovery, validation, and analysis. With a global presence and subsidiaries like EMD Millipore Corporation and Merck Biosciences AG, Merck has strengthened its position through strategic partnerships. In January 2025, it collaborated with Qpentions Labworks to automate assay workflows with the Flex robotic workstation, enhancing protein sample preparation. Additionally, in June 2024, Merck partnered with the Michael J. Fox Foundation to support the SMCXPRQ immunoassay platform for detecting low-abundance biomarkers related to early Parkinson's disease. This focus on automation and disease-specific advancements highlights Merck's significant role in the global biomarker market. For more information, Inquire Now! Related Reports: Cancer Biomarkers Market Cardiac Marker Testing Market Cancer Profiling Market Companion Diagnostics Market PCR Technologies Market Get access to the latest updates on Biomarkers Companies and Biomarkers Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content:
Malaysian Reserve
a day ago
- Malaysian Reserve
Argo Corporation Reports First Quarter 2025 Financial Results
TORONTO, May 30, 2025 /CNW/ – Argo Corporation (TSXV: ARGH), (OTCQX: ARGHF) ('Argo' or the 'Company'), a leader in next-generation transit solutions, announced its financial results for the quarter ended March 31, 2025 ('Q1 2025'). All figures are in Canadian dollars unless otherwise noted. Municipal Deployments Argo has made significant progress in the commercialization of its Smart Routing™ technology. The Company's first municipal deployment in the town of Bradford West Gwillimbury launched in the second quarter of 2025, as previously announced by the Company. Argo also announced its landmark $10.9 million 12-month pilot with the City of Brampton in the second quarter of 2025, anticipated to launch later this year. While revenue from these agreements was not reflected in Q1 2025 results, the Company expects to begin recognizing related revenues in the second and third quarters of 2025. Argo continues to advance a robust pipeline of municipal opportunities, positioning the Company for continued growth. Research & Development of Smart Routing™ Transit System In Q1 2025, the Company continued its investment in research and development to enhance its proprietary Smart Routing™ hardware and AI-powered software ecosystem, including vertical integration hardware onboard its Argo X1 electric vehicles. This end-to-end platform combines real-time routing software, electric vehicles and full-service operations to deliver dynamic, on-demand transit services. FoodsUp Inc. The company held a 47.851% interest in FoodsUp Inc. ('FoodsUp') as of March 31, 2025. FoodsUp is one of Canada's leading restaurant supply platforms, with annual revenues of $108 million in fiscal 2024. As previously disclosed, the Company made significant progress towards the divestment of this ownership interest in Q1 2025: Sale of Shares: The Company received approximately $2.5 million in proceeds from the sale of an aggregate of 5,855 subordinate-voting shares of FoodsUp Inc. Option Agreements: The Company entered into two option agreements (collectively, the 'Option Agreements') granting the holders thereof the irrevocable option to purchase up to a total of 45,932 subordinate-voting shares of FoodsUp. If the transactions contemplated by the Option Agreements are fully exercised, the Company has the potential to receive gross proceeds of between $21.6 million and $30.2 million. The Company's ability to complete the transactions provided for in the Option Agreements remain subject to any required approvals, including final approval of the TSX Venture Exchange and approval of the shareholders of the Company. In addition, in the second quarter of 2025, the Company announced that its board of directors declared a special stock dividend (the 'Stock Dividend') intended to provide its legacy shareholders with their proportionate stake in the net proceeds realized upon the eventual sale by the Company of its ownership interest in FoodsUp. Pursuant to the Stock Dividend, all of the Company's common shareholders of record on August 13, 2025 (the 'Record Date') will be entitled to receive, one Preferred Share, Series A of Argo for each common share of Argo held on the Record Date. The payment date for the Stock Dividend is August 20, 2025. Additional details regarding the Stock Dividend can be found in the Company's press release dated May 21, 2025. For detailed information, please refer to Argo's condensed interim consolidated financial statements for the three months ended March 31, 2025, and 2024 ('Q1 2025 Financial Statements') and its management's discussion and analysis of financial condition and results of operations for the three months ended March 31, 2025, and 2024 (the 'Q1 2025 MD&A'), filed on SEDAR+ at The following table provides a summary of Argo's financial results for the three months ended March 31, 2025 and 2024: For the three months ended March 31 2025 2024 REVENUE $512,172 $219,585 Cost of revenue $115,987 $12,956 General and administration 2,570,907 966,946 Operational support 663,431 239,207 Research and development 224,492 49,174 Sales and marketing 10,648 34,802 Provision for trade and other receivables – – Amortization & depreciation 18,490 34,746 Depreciation 25,989 7,584 Total operating expenses 3,629,944 1,345,415 OPERATING LOSS ($3,117,772) ($1,125,830) OTHER INCOME (EXPENSES) Foreign exchange gain/ (loss) (14,791) (40,069) Interest expenses (427,312) (228,616) Interest income – 897 Loss on termination (996,968) – Write-off of accounts payable settlements – 98,202 Fair value gain (loss) on investments 2,726,221 – Gain on sale of investment 105,864 – Share of loss of an associate – (1,083,495) Net income/ (loss) from continuing operations ($1,724,758) ($2,378,911) Discontinued Operations Net gain/(loss) from discontinued operations, net of tax 497 (489,791) Gain from derecognition, net of tax – 1,341,770 NET GAIN (LOSS) ($1,724,261) ($1,526,932) Cumulative translation adjustment (342) 78,655 Cumulative translation adjustment for discontinued operations – (252,661) NET PROFIT (LOSS) AND COMPREHENSIVE PROFIT (LOSS) ($1,724,603) ($1,700,938) (Loss) Profit per share (Loss) income per share from continuing operations – Basic and diluted ($0.01) ($0.02) Income (loss) per share from derecognition and discontinued operations – Basic and diluted $0.00 $0.01 Weighted average shares outstanding – Basic and diluted 138,683,002 132,944,615 All figures rounded to the nearest dollar. Prepared in accordance with IFRS. About Argo Argo delivers the world's first fully vertically integrated transit system, combining Argo X1 electric vehicles, Smart Routing™ technology, and comprehensive operational management in a single end-to-end solution. By integrating every aspect of the transit experience, Argo enables municipalities to augment traditional fixed-route services to dynamically optimized on-demand service while maintaining standard public transit pricing. The company launched Argo School in September 2024 and began its first municipal deployment in Bradford West Gwillimbury in early 2025. Learn more at Praveen Arichandran, CEOArgo Corporation(800) 575-7051 Forward-Looking Information This news release includes certain forward-looking statements as well as management's objectives, strategies, beliefs and intentions. Forward-looking statements are frequently identified by such words as 'may', 'will', 'plan', 'expect', 'anticipate,' 'estimate,' and 'intend,' and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. The forward- looking information set out in this news release relates to future events or our future performance and includes, without limitation, statements concerning the recognition of revenue in future quarters, the future growth of the Company, the completion of the completion of the exercise of the options granted pursuant to the Option Agreements by the holders thereof, Argo's ability to obtain all necessary approvals in respect of the Option Agreements and the Stock Dividend, and Argo's intention with respect to the Stock Dividend. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, as described in more detail in the Company's securities filings available at Actual events or results may differ materially from those projected in the forward-looking statements, and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law. See 'Cautionary Note Regarding Forward-Looking Information', 'Financial Risk Management Objectives And Policies' and 'Other Business Risks and Uncertainties' in the Company's Q1 2025 Financial Statements and its Q1 2025 MD&A for a discussion of the uncertainties, risks and assumptions associated with these statements and other risks. Readers are urged to consider the uncertainties, risks, and assumptions carefully when evaluating forward-looking information and are cautioned not to place undue reliance on such information. We have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities legislation and regulatory requirements. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
